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Abstract 
Nerve preservation is an important issue during most surgery because accidental transection or 
injury results in significant morbidity, including numbness, pain, weakness, or paralysis. Currently, 
nerves are still identified only by gross appearance and anatomical location during surgery, without 
intraoperative image guidance. Near-infrared (NIR) fluorescent light, in the wavelength range of 
650-900 nm, has the potential to provide high-resolution, high-sensitivity, and real-time avoidance 
of nerve damage, but only if nerve-specific NIR fluorophores can be developed. In this study, we 
evaluated a series of Oxazine derivatives to highlight various peripheral nerve structures in small 
and large animals. Among the targeted fluorophores, Oxazine 4 has peak emission near into the 
NIR, which provided nerve-targeted signal in the brachial plexus and sciatic nerve for up to 12 h 
after a single intravenous injection. In addition, recurrent laryngeal nerves were successfully 
identified and highlighted in real time in swine, which could be preserved during the course of 
thyroid resection. Although optical properties of these agents are not yet optimal, chemical 
structure analysis provides a basis for improving these prototype nerve-specific NIR fluorophores 
even further. 
Key words: Real-time intraoperative identification, nerve targeting, recurrent laryngeal nerve, 
contrast agents, targeted agents, near-infrared imaging. 
Introduction 
Nerve damage during surgery results in signifi-
cant morbidity and mortality [1-4]. Despite advance-
ments in surgical technique and equipment, nerves 
are currently identified via gross appearance and an-
atomical location, without intraoperative image 
guidance. Thin or buried nerves are at high risk for 
damage. Anatomical variants such as bifurcation, tri-
furcation, medial or anterior displacement, and 
non-recurrence are also risk factors for injury [5,6]. 
For example, recurrent laryngeal nerve (RLN) injury 
in the neck can cause symptoms ranging from 
hoarseness and aspiration in unilateral injury, to life 
threatening airway obstruction in the case of bilateral 
injury [2,7]. To minimize such high morbidity and 
mortality from nerve injury, intraoperative visual 
identification during complex surgery is of para-
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mount importance.  
However, only 3 main classes of nerve-specific 
molecules have been reported to date, including stil-
bene derivatives, distyrylbenzene (DSB) fluorophores, 
and styryl pyridinium (FM) fluorophores [8-11]. 
Among these agents, DSBs such as BMB, GE3082, and 
GE3111 have been investigated for image-guided 
nerve surgery [12-14]. However, none of these com-
pounds were optimal because of high adsorption and 
scattering in tissues from the ultraviolet and visible 
wavelengths required. In addition, due to their in-
trinsically high lipophilicity and charge, they exhibit 
high background binding to adipose tissues, thus 
lowering the signal-to-background ratio (SBR) con-
siderably. Relatively high endogenous tissue auto-
fluorescence in the visible wavelength range also lim-
its the use of these fluorophores in vivo [15].  
To overcome these limitations, nerve-specific 
contrast agents in the near-infrared (NIR) range are 
desperately needed. Recently, Whitney et al. synthe-
sized peptides that localize to nerve-associated con-
nective tissues [16]. They highlighted almost all 
nerves in the body including motor and sensory 
nerves, but only after labeling with exogenous fluor-
ophores [16,17]. Gustafson et al. developed a NIR 
fluorophore, which is hydrophilic indocyanine green 
(ICG) analogue, for peripheral nerve targeting [18]. 
Gibbs et al. investigated the structure-activity rela-
tionship of over 200 nerve-specific contrast agents and 
also screened these molecules for NIR optical proper-
ties. Although no NIR agents were obtained, several 
putative fingerprints for nerve uptake were identified 
[13]. Based on these results, we investigated Oxa-
zine-based chemical structures for simultaneous 
nerve uptake and NIR fluorescence. Our goal is to 
develop nerve-specific agents in the NIR range [19], 
which permits color video and NIR to be acquired 
simultaneously, thus providing real time im-
age-guidance to surgeons about nerve location. 
Materials and Methods 
Optical Property Measurements. Oxazine de-
rivatives were obtained from Fisher Scientific Inc. 
(Pittsburgh, PA) or Sigma-Aldrich (Saint Louis, MO), 
and BMB was synthesized as described previously 
[20]. Optical measurements were performed at 37°C 
in phosphate-buffered saline (PBS), pH 7.4 or 100% 
fetal bovine serum (FBS) buffered with 50 mM 
HEPES, pH 7.4. Absorbance and fluorescence emis-
sion spectra were measured using fiber optic HR2000 
absorbance (200–1100 nm) and USB2000FL fluores-
cence (350–1000 nm) spectrometers (Ocean Optics, 
Dunedin, FL). A 532 nm green laser pointer (Opcom 
Inc., Xiamen, China) set to 5 mW and coupled through 
a 300 µm core diameter, NA 0.22 fiber (Fiberguide 
Industries, Stirling, NJ) was used to excite fluoro-
phores and avoid spectral overlapping between the 
laser excitation and fluorescence emission. In silico 
calculation of the partition coefficient (logD at pH 7.4) 
was calculated using Marvin and JChem calculator 
plugins (ChemAxon, Budapest, Hungary). Chemical 
similarities were calculated by Instant JChem 6.04 
using “Chemical Hashed Fingerprint” with the Nor-
malized Euclidean dissimilarity screening configura-
tion (ChemAxon).  
NIR Fluorescence Imaging System. The du-
al-NIR channel FLARE imaging system has been de-
scribed in detail previously [21-23]. In this study, a 670 
nm excitation was used at a fluence rate of 4 mW/cm2, 
with white light (400–650 nm) at 40,000 lx. Color and 
NIR fluorescence images were acquired simultane-
ously with custom software at rates up to 15 Hz over a 
15 cm diameter field of view. A pseudo-colored lime 
green was used for NIR fluorescence in the color-NIR 
merged images. The imaging system was positioned 
at a distance of 18 inches from the surgical field.  
Ex Vivo Nerve-Specific Fluorophore Screening. 
Sciatic nerves from female Yorkshire pigs were har-
vested, fixed in 2% paraformaldehyde (PFA), and 
flash frozen in optimal cutting temperature (OCT) 
compound using liquid nitrogen. Human sural nerve 
tissue was provided by the Chonnam National Uni-
versity Medical School in a paraffin block, and swine 
sciatic nerve was obtained from a Yorkshire pig prior 
to injecting fluorophores. Nerve tissues were cut in 
cross section using a cryostat at 10 μm thickness onto 
positively charged glass slides. Tissue sections were 
washed once with PBS for 2 min to remove residual 
OCT. The tissue was then fixed to the slide with 2% 
PFA for 15 min, followed by washing with PBS (3 x 5 
min). A formulation was previously developed for 
intravenous (IV) administration and was used in the 
current study to incubate the fluorophores with the 
nerve tissue [20]. All fluorophores were mixed from 
the 100 mM stock solution into the IV formulation 
(D5W containing 5% Cremophor EL) at 100 μM and 
incubated with the washed nerve tissue sections at 
room temperature for 20 min. Additional IV formula-
tion not containing fluorophore was mixed and used 
to wash each nerve section twice (5 min per wash) 
following incubation with the formulated fluoro-
phore. The nerve section was then washed an addi-
tional 2 times with PBS (5 min per each), after which 
coverslips were mounted using Fluoromount-G 
(Southern Biotech, Birmingham, AL). 
NIR fluorescence microscopy for ex vivo nerve 
tissue slides was performed on a Nikon Eclipse TE300 
microscope system as previously described [12,20,24]. 
The microscope was equipped with a 100 W mercury 
light source, NIR-compatible optics, and a 
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NIR-compatible 4X, 10x, and 20X Plan Fluor objective 
lens (Nikon, Melville, NY). Images were acquired on 
an Orca-AG (Hamamatsu, Bridgewater, NJ). Image 
acquisition and analysis was performed using IPLab 
software (Scanalytics, Fairfax, VA). A custom filter set 
(Chroma Technology Corporation, Brattleboro, VT) 
composed of a 650/44 nm excitation filter, a 675 nm 
dichroic mirror, and a 710/50 nm emission filter were 
used for 700 nm NIR imaging, while ET710/75x, 
T760lpxr, and ET810/90m were used for 800 nm NIR 
imaging. For BMB, a mercury light source was passed 
through a 360/50 nm BP excitation filter, a 400 nm LP 
beam splitter, and a 550/50 nm emission filter.  
Animal Models. Animals were housed in an 
AAALAC-certified facility. Animal studies were per-
formed under the supervision of Beth Israel Deacon-
ess Medical Center’s Institutional Animal Care and 
Use Committee (IACUC) in accordance with ap-
proved institutional protocols (#101-2011 for rodents 
and #046-2010 for pigs). Male CD-1 mice weighing ≈ 
25 g and Sprague-Dawley rats weighing ≈ 250 g 
(Charles River Laboratories, Wilmington, MA) were 
anesthetized with 100 mg/kg ketamine and 10 mg/kg 
xylazine intraperitoneally (Webster Veterinary, Fort 
Devens, MA). Female Yorkshire pigs (E.M. Parsons 
and Sons, Hadley, MA) averaging 37 kg were induced 
with 4.4 mg/kg intramuscular Telazol (Fort Dodge 
Labs, Fort Dodge, IA), intubated, and maintained 
with 2% isoflurane (Baxter Healthcare Corp., Deer-
field, IL). Following anesthesia, electrocardiogram, 
heart rate, pulse oximetry, and body temperature 
were monitored throughout surgery. The number of 
animals (N) used for each targeting and imaging ex-
periment was 5.  
Intraoperative Nerve-Targeting and Imaging. 
For intravenous (IV) injection, each fluorophore was 
dissolved in D5W containing 5% Cremophor EL at a 2 
mM concentration. Initial in vivo screening occurred in 
Sprague Dawley rats by injecting 1 µmol of each 
fluorophore based on our previous study of BMB 
(Supplementary Material: Supplementary Methods) 
[20]. For kinetic and dose-response studies, 50 – 400 
nmol of Oxazine 4 was injected intravenously into 
CD-1 mice and measurements taken over 24 h (N = 5 
per dose and time point). Control images were ac-
quired prior to injecting NIR fluorophores. The fluo-
rescence signal in nervous tissues and sig-
nal-to-background ratio (SBR) compared to neigh-
boring muscle (Mu) was obtained over the period of 
imaging. For the large animal study, the optimal dose 
found in mice (200 – 400 nmol per mouse) was used in 
pigs by scaling to body surface area [25,26]. 20 – 40 
µmol (0.17 – 0.34 mg/kg) of Oxazine 4 was injected 
intravenously into Yorkshire pigs and the fluores-
cence images of recurrent laryngeal nerve (RLN), 
brachial plexus (BP), and sciatic nerve (SN) were ob-
served in real time using the FLARE imaging system 
up to 4 h post-injection (N = 5 subjects). 
Quantitation and Statistical Analysis. The flu-
orescence intensity (FI) and background (BG) inten-
sity of a region of interest (ROI) over each 
nerve/tissue were calculated and quantified using 
custom FLARE software. The FI of the RLN, BP, and 
SN at the optimal dose and time point were quantified 
to measure tissue-specific targeting. Adjacent tissues 
such as trachea (Tr), thyroid (Th), tracheoesophageal 
groove (TEG), muscle (Mu), and adipose tissue (Ad) 
were used as background to calculate the SBR of RLN, 
BP, and SN in pigs. Statistical analysis was carried out 
using a one-way ANOVA followed by Tukey’s mul-
tiple comparisons test. Results were presented as 
mean ± S.D. and curve fitting was performed using 
Prism version 4.0a software (GraphPad, San Diego, 
CA). 
Hematoxylin and Eosin (H&E) Histology and 
Immunohistochemistry (IHC). RLN, BP, and SN 
were extracted from rats and pigs 4 h post-injection 
and placed in 2% paraformaldehyde for 30 min before 
mounting in Tissue-Tek OCT compound (Fisher Sci-
entific, Pittsburgh, PA) and flash-freezing in liquid 
nitrogen. Frozen samples were cryosectioned (10 µm 
per slice); 1 slide was stained with H&E and consecu-
tive sections were used for fluorescence microscopy 
and IHC. For IHC, rabbit anti-myelin basic protein 
(MBP; #ab53294, Abchem) and goat anti-rabbit IRDye 
800CW (#827-08365, Li-Cor) were used to visualize 
myelin sheath. NIR fluorescence microscopy was 
performed as described above for the ex vivo assay, 
where Oxazine 4 and MBP antibody were imaged by 
700 nm and 800 nm NIR channels, respectively.  
 
Results  
Chemical and Optical Properties. As shown in 
Fig. 1, a series of symmetric Oxazine derivatives 
having cationic pendant groups were explored for 
nerve-specific targeting ex vivo and in vivo. BMB (ul-
traviolet excitation, visible emission) was used as a 
positive control. Oxazine 1 and Oxazine 4 have rela-
tively high extinction coefficients (> 140,000 M-1cm-1) 
and a moderate Stokes shift (> 17 nm) in 100% serum, 
pH 7.4 (Table 1 and Supplementary Material: Fig. S1). 
The logD at pH 7.4 of BMB, Oxazine 170, and Oxazine 
750 are higher than 3.5, while Oxazine 1 and Rhoda-
mine 800 had values less than 1. The logD at pH 7.4 of 
Oxazine 4 is 3.38 with a MW of 395.84 (Table 1 and 
Supplementary Material: Fig. S1). 
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Figure 1. Chemical Structure of Nerve-Targeting Fluorophores. Oxazine 1 is also known as Oxazine 725. 
 
Table 1. Chemical and Physical Properties of Nerve-Targeting Fluorophores. 
Fluorophore MW 
(Da) 
LogD,  
pH 7.4 
PSA 
(Å2) 
HBD/ 
HBA 
Rotat. 
Bonds 
λ 
(M-1cm-1) 
Abs  
(nm) 
Em  
(nm) 
SBR 
Ex vivo In vivo 
BMB 364.06 4.84 61.27 2/3 5 52,800 397 498 + + 
Oxazine 1 423.89 0.33 27.84 0/3 5 196,000 655 670 – – 
Oxazine 4 395.84 3.38 47.59 2/3 3 143,000 616 635 ++ +++ 
Oxazine 170 431.87 3.94 47.59 2/3 3 69,000 625 650 + + 
Oxazine 750 469.92 4.67 38.80 1/3 1 44,000 676 684 + – 
Rhodamine 800 495.95 0.43 39.27 0/3 0 68,000 697 710 + – 
MW = molecular weight; PSA = polar surface area; HBD/HBA = H bond donors/acceptors; Rotat. Bonds = rotational bonds; λ = extinction coefficient; Abs = peak absorb-
ance; Em = peak emission. The SBR of each nerve relative to the neighboring adipose tissue was quantified and labeled as –, < 1; +, 1 to 2; ++, 2 to 3; and +++, > 3. 
 
 
Ex Vivo Nerve-Specific Fluorophores Screen-
ing. BMB, Oxazine 1, Oxazine 4, Oxazine 170, Oxazine 
750, and Rhodamine 800 fluorophores were screened 
for nerve-specific fluorescence and undesired adipose 
uptake using cross sections of pig sciatic nerve (Sup-
plementary Material: Fig. S2) and human sural nerve 
tissue (Fig. 2a). Fluorescence images of Oxazine de-
rivatives were compared with the previously identi-
fied nerve-specific fluorophore BMB (positive con-
trol). Oxazine 4, Oxazine 750, and Rhodamine 800 
fluorophores exhibited strong fluorescence signal 
throughout the cross-sectioned nerve fascicle, while 
Oxazine 1 and 170 showed weak nerve-specific fluo-
rescence signal. Although the positive control BMB 
represented relatively high fluorescence in the nerve, 
the signal in epineurium and adipose tissues was even 
higher than the target signal (SBR < 1.0). From this ex 
vivo nerve-specific screening Oxazine 4, Oxazine 750, 
and Rhodamine 800 were identified as the potential 
candidates for high performance in vivo.  
In Vivo Nerve-Specific Fluorophores Screen-
ing. Initial screening of fluorophore performance in 
vivo utilized a single intravenous injection of BMB and 
Oxazine derivatives at a dose of 1 µmol in 250 g SD 
rats 4 h prior to imaging (Fig. 2b). To compare the 
difference between ex vivo and in vivo results, all 
fluorophores used in ex vivo screening were examined 
in vivo in the rat brachial plexus and sciatic nerve as-
says. Oxazine 4 showed the highest nerve-specific 
fluorescence signal and the lowest background (mus-
cle and adipose tissue) fluorescence signal compared 
to other molecules and BMB. Although Oxazine 1 
showed no nerve fluorescence by the ex vivo nerve 
screening assay, it did have a weak signal in the vi-
cinity of nerve, but could also have been caused by 
high adipose tissue uptake. Based on these data, Ox-
azine 4 was chosen for further study.  
Kinetics of Oxazine 4 Nerve Targeting in CD-1 
Mice. To determine the time of peak SBR, we injected 
100 nmol (1.6 mg/kg) of Oxazine 4 into mice and sac-
rificed N = 5 per time point. The fluorescence signal in 
the BP and SN was bright enough by 1 h 
post-injection, however, the SBR was low because of 
high background signal from the salivary gland, ad-
jacent muscle, adipose tissue, and skin. The highest 
SBR ≈ 3.0 was achieved at 4 h post-intravenous injec-
tion, at which point surrounding background signal 
had decreased significantly (*P < 0.05). Oxazine 4 up-
take was higher in the brachial plexus compared to 
sciatic nerve, of which signal retained up to 12 h. The 
background signal completely diminished after 24 h 
of a single IV injection, but the fluorescence signal in 
nervous tissues also decayed over time (Fig. 3a). 
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Figure 2. Ex Vivo and In Vivo Screening Assay of Fluorophores for Nerve-Specificity. A) Nerve-specific fluorescence intensity was determined using staining of human sural nerve 
cut in cross section and incubated with 100 µM of each fluorophore. Ep = epineurium; F = nerve fascicle. Scale bars = 200 µm. The partition coefficient (logD at pH 7.4) was 
calculated using JChem calculator plugins. B) In vivo nerve-specific fluorescence in the rat brachial plexus (BP, top rows) and sciatic nerve (SN, bottom rows) 4 h post-injection. 
Arrowheads indicate fluorescence signals in nerve tissue. SG = salivary gland. Scale bars = 1 cm. All NIR fluorescence images have identical exposure and normalizations. 
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Figure 3. Kinetics and Dose-Response of Oxazine 4 Uptake in Mice. A) Quantitative time-course assessment of SBR (mean ± SEM) for brachial plexus (BP) and sciatic nerves 
(SN). 100 nmol (1.6 mg/kg) of Oxazine was injected intravenously into CD-1 mice, and SBR (BP/Mu) and SBR (SN/Mu) were measured at different time points (T = 0, 1, 4, 6, 12, 
and 24 h). Arrowheads indicate fluorescence signals in nerve bundles. SG = salivary glands; Mu = muscle. B) Dose-response curve of SBR (mean ± SEM) for BP and SN. 0, 50, 100, 
200, and 400 nmol of Oxazine 4 were injected intravenously into CD-1 mice, and SBR (BP/Mu) and SBR (SN/Mu) were measured at 4 h post-injection. Arrowheads indicate 
fluorescence signals in nerve bundles. Images are representative of N = 5 independent experiments. **P < 0.01 and *P < 0.05. SG = salivary glands; Mu = muscle. Scale bars = 1 
cm. All NIR fluorescence images have identical exposure times (500 msec) and normalizations.  
 
Dose-Dependence of Oxazine 4 Nerve Target-
ing in CD-1 Mice. Dose-dependent optimization was 
investigated at 4 h post-injection. As shown in Fig. 3b, 
the fluorescence signals in the BP and SN were pro-
portional to the injected dose in the range of 50 – 400 
nmol per mouse (0.8 – 6.3 mg/kg). The minimal dose 
used to highlight peripheral nerves was 50 nmol, 
however, a significant increase in nerve signals was 
found when injected with 200 nmol of Oxazine 4 (**P 
< 0.01 for BP and *P < 0.05 for SN). Although the 
maximum nerve signal was obtained with the IV in-
jection of 400 nmol Oxazine 4, the background signals 
in the surrounding muscle and adipose tissues were 
significantly increased as well. Therefore, no signifi-
cant differences were observed in the SBR of BP and 
SN between the dose of 200 nmol and 400 nmol (P > 
0.05). 
Optimal Nerve Targeting Using Oxazine 4 in 
SD Rats. The BP and SN were clearly identified and 
highlighted after a single intravenous injection of 
Oxazine 4 in CD-1 mice. However, branched periph-
eral nerves are not identified because of difficulty in 
visual identification. To find out branched nerves in 
small animals, we injected 1 µmol of Oxazine 4 intra-
venously into SD rats 4 h prior to imaging based on 
the optimized condition in Fig. 3. As indicated by 
arrowheads, small branches of main nerves including 
BP and SN could be identified in the fluorescence 
images that could not be distinguished visually using 
color video (Fig. 4a). In addition, the nervous struc-
ture was confirmed by IHC using an anti-myelin basic 
protein (MBP) antibody. MBP is a major component of 
multilayered myelin sheath and interact with the li-
pids in the myelin membrane [14,27]. As shown in 
Fig. 4b, Oxazine 4 colocalizes with the myelinated 
sheath within the fascicle, which was stained by the 
MBP antibody.  
Oxazine 4 Nerve Targeting in Large Animals. 
Various sites of important peripheral nerves were 
surgically exposed and imaged with Channel 1 (≈ 700 
nm) of the FLARE imaging system at 5, 15, 30, 60, 120, 
180, and 240 min post-injection (Fig. 5). In the 
pre-injection images, RLN, BP, and SN show almost 
no autofluorescence, however, thyroid (Th) shows 
relatively high autofluorescence. Since the RLN is 
usually located in the tracheoesophageal groove 
(TEG), the SBR between nerves and adjacent tissues 
such as trachea, TEG, and Th is the key determinant 
for preserving the RLN during surgery. The fluores-
cence signal in the RLN was relatively high by 30 min 
post-injection, however, excessive signals remained in 
the surrounding tissues. Therefore, the maximal SBR 
was achieved 3 h post-injection (Fig. 5a). This time 
span should be enough to identify thin and buried 
RLNs and avoid nerve damage during thyroidectomy 
in real time. On the other hand, BP and SN were rela-
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tively easily identified at early time points, and the 
maximal SBR for BP and SN was achieved at 1 h and 2 
h post-injection, respectively. As shown in Fig. 5b, the 
signals in nervous tissue retained up to 4 h 
post-injection. In order to see the reliability of in-
traoperative RLN mapping for thyroid patients who 
get reoperation after thyroidectomy, we removed 
thyroid and observed RLN and surrounding tissues 
(Fig. 5b). The absence of thyroid improved the identi-
fication of RLN in real time, and the SBR of RLN with 
neighboring tissue was higher than 1.0. Additionally, 
nerves were resected and cryosectioned for H&E and 
fluorescence microscopy. As shown in Fig. 5c, NIR 
fluorescence microscopic images confirm bright fluo-
rescence signal throughout the nerve, which indicates 
the entire endoneurium surrounding individual axon 
and myelinated fibers within the fascicle could be 
stained by the single intravenous injection of Oxa-
zine 4.  
Quantitative Structure-Activity Relationships 
(QSAR). Based on the QSAR screening and chemical 
group fingerprinting of BMB [13], we compared the 5 
positive fingerprints with our new nerve-targeting 
fluorophores. Among the series, Oxazine 4 met the 
basic requirement of a balanced para configuration of 
the core (Supplementary Material: Fig. S4; [13]). In 
addition, Oxazine 4 showed the highest similarity 
with the 5 highest ranked fingerprints except for BMB. 
As shown in Fig. 6, when compared to the chemical 
structure of BMB and its constituent groups, Oxazine 
4 also ranked top in most cases. Rhodamine 800 
scored higher for some fragments, but its uptake in 
nerve was low because of its low logD at pH 7.4 (0.43). 
Conversely, Oxazine 170 and Oxazine 750, which 
have high logD at pH 7.4 values (3.94 and 4.67, re-
spectively) showed strong adipose uptake both ex vivo 
and in vivo.  
 
 
Figure 4. In Vivo Nerve-Specific Targeting using Oxazine 4 in Rats. A) 1 µmol of Oxazine 4 was injected intravenously into SD rats 4 h prior to imaging. Shown are color image, 
NIR fluorescence, a merged image of the two (pseudo-colored in lime green), and magnified images of NIR fluorescence acquired using the FLARE imaging system. Arrowheads 
indicate small branches of main nerves, which cannot be seen in color image. Scale bars = 1 cm. B) H&E, phase image, NIR fluorescence (Oxazine 4, 700 nm NIR), and im-
munostaining (right) of small branched peripheral nerves obtained from A using an anti-myelin antibody conjugated with IRDye 800CW. Squares on low-resolution images 
indicate the positions of magnified images. Pseudo-colored red and green colors were used for 700 nm and 800 nm channel images, respectively. Scale bars = 100 µm. Images are 
representative of N = 5 independent experiments. All NIR fluorescence images have identical exposure and normalizations. 
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Figure 5. Kinetics of Oxazine 4 Uptake in Pig Nerves. A) Quantitative time course assessment of SBR (mean ± SEM) for recurrent laryngeal nerve (RLN), brachial plexus (BP), 
and sciatic nerve (SN). 20 µmol (0.25 mg/kg) of Oxazine 4 was injected intravenously into 35 kg Yorkshire pigs, and the SBR of nerves to the specified surrounding tissue was 
measured at different time points (T = 0, 15, 30, 60, 120, 180, and 240 min). B) Real-time intraoperative fluorescence images of RLN (top), BP (middle), and SN (bottom) acquired 
at different time points (T = 0, 1, 2, and 4 h). Thyroid was resected (thyroidectomy) after 4 h, and RLN was highlighted without signal interruption. Ad = adipose tissue; Mu = 
muscle; TEG = tracheoesophageal groove; Th = thyroid; Tr = trachea. Scale bars = 1 cm. C) Fluorescence microscopic images of cryosectioned RLN, BP, and SN. Samples were 
obtained after injecting 20 µmol of Oxazine 4 into Yorkshire pigs 4 h prior to resection. Shown are representative images (N = 5) of H&E (left) and NIR fluorescence (right) 
images. Blue squares on H&E images indicate the positions of magnified images. Scale bars = 100 µm. All NIR fluorescence images have identical exposure times and normali-
zations.  
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Figure 6. Chemical Similarities between Non-NIR and NIR Nerve-Specific Contrast Agents. BMB (non-NIR) and Oxazine 4 (NIR) are shown as 2D energy-minimized structures, 
3D structures with charge (red = negative; blue = positive) and hydrophobicity (gray) distributions, and in comparison to BMB and its sub-structures. Similarity was calculated 
using the chemical hashed fingerprint method with a Normalized Euclidean screening configuration (Instant JChem v 6.04, ChemAxon). 
 
Discussion  
Image-guided surgery is now in routine clinical 
use to improve surgical fields by using interventional 
MRI, ultrasound, and electrophysiological recordings. 
However, limitations remain in regard to visualizing 
and guiding thin or buried nerves due to the lack of 
nerve-specific imaging [28]. Most recently, Tsien and 
colleagues made a significant improvement in 
nerve-specific targeting and imaging, where an engi-
neered peptide FAM-NP41 was used to label in vivo 
animal nerves and resected human RLN with rela-
tively high affinity [16]. Since small molecules are 
about 10-1000 fold smaller than peptides and proteins, 
however, they will need at least 10-fold less dosage if 
the affinity is identical. It should be noted that the 
optimal dose of the molecules we describe in this 
study is 10-50 fold lower than previously described 
nerve-specific fluorophores [11-13,16] and corre-
sponds to a human equivalent dose of only 0.25 
mg/kg [25,26], which is consistent with the clinical-
ly-approved dose of the NIR fluorophore indocyanine 
green (ICG). Importantly, at this dose range, Oxazine 
4 does not stain the central nervous system, and did 
not show apparent impairment of motor function and 
sensory integrity during the 24 h post-injection (data 
not shown).  
Furthermore, the modification of physicochem-
ical properties of small molecules is relatively easy for 
real-time image guided surgery [29]. To develop an 
ideal nerve-specific contrast agent for image-guided 
surgery, we need to consider the following criteria: 1) 
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logD at pH 7.4 between 0.5 to 3 and molecular weight 
< 500 Da to maximize blood-nerve-barrier (BNB) 
penetration, 2) excitation and emission wavelengths 
in the NIR window, and 3) prolonged retention in the 
nerve tissue [30]. To the best of our knowledge, Oxa-
zine 4 is the first small molecule described to date that 
closely meets all criteria. Based on its chemical simi-
larity to BMB, Oxazine 4 likely targets myelin or a 
closely associated molecule. Nonetheless, it should be 
considered a prototype molecule because the optical 
property of Oxazine 4 is not in the true NIR window. 
Additionally, biodistribution and clearance should be 
considered because they mediate the fate of contrast 
agents in vivo such as how long after intravenous in-
jection a contrast agent reaches peak SBR, and how 
long the signal lasts. The nerve-specific signals may 
vary depending on the species because of different 
biodistribution, metabolism, and pharmacokinetics. 
However, the pharmacokinetic data presented in both 
small and large animals suggest that nerve penetra-
tion is rapid, blood and tissue clearance is rapid, yet 
retention in nerves is strong enough to permit an SBR 
> 1 for 3-4 hours, which is good enough for compli-
cated nerve surgery. After optimizing the optical and 
chemical properties described above, attention will 
need to be turned to nerve affinity. Increasing affinity 
will further improve nerve retention while also in-
creasing signal strength and the imaging period.  
In summary, near-infrared fluorescent, 
nerve-specific small molecules could be considered 
the Holy Grail in the field of image-guided surgery. 
Although our work does not conclude the quest, it 
lays the foundation for another push towards the goal 
by helping surgeons to avoid nerve damage on a pa-
tient-specific basis. 
Supplementary Material 
Supplementary methods, Fig.S1 - Fig.S5. 
http://www.thno.org/v04p0823s1.pdf 
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